| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 01/22/2004 | CA2491077A1 Furopyridine and furopyrimidine derivatives for the treatment of hyper-proliferative disorders |
| 01/22/2004 | CA2490818A1 Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/22/2004 | CA2489084A1 A process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
| 01/21/2004 | EP1382616A2 Pharmaceutical composition for use in the treatment of abnormalities associated with the activity of a human Y5-receptor |
| 01/21/2004 | EP1382606A2 8-azabicyclo[3.2.1]octane derivatives and their use as anticholinergics |
| 01/21/2004 | EP1382333A2 Use of beta 3 adrenergic receptor agonists in the treatment of dysuria |
| 01/21/2004 | EP1381681A1 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use |
| 01/21/2004 | EP1381631A2 Human timp-1 antibodies |
| 01/21/2004 | EP1381626A2 Human transporters and ion channels |
| 01/21/2004 | EP1381620A2 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations |
| 01/21/2004 | EP1381611A1 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic |
| 01/21/2004 | EP1381608A1 Cyclohexylphenyl vasopressin agonists |
| 01/21/2004 | EP1381606A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| 01/21/2004 | EP1381602A1 Heterocyclyldicarbamides as caspase inhibitors |
| 01/21/2004 | EP1381594A1 Urea compounds useful as anti-inflammatory agents |
| 01/21/2004 | EP1381592A1 1,4-disubstituted benzo-fused compounds |
| 01/21/2004 | EP1381590A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| 01/21/2004 | EP1381376A2 In vivo use of water absorbent polymers |
| 01/21/2004 | EP1381371A2 Hormone replacement therapy |
| 01/21/2004 | EP1381370A1 N-biphenylcarbonyl- and n-phenylpyridylcarbonyl substituted bi- and tricyclic azepines and diazepines as vasopressing agonists |
| 01/21/2004 | EP1381369A1 Use of selective cox-2 inhibitors for the treatment of urinary incontinence |
| 01/21/2004 | EP1280799B1 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 01/21/2004 | EP1242415B1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 01/21/2004 | EP1126852B1 Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| 01/21/2004 | EP1019048B1 Use of an angiotensin ii receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients |
| 01/21/2004 | EP0752871B1 Adhesion inhibiting vaccinium extract |
| 01/21/2004 | EP0734263B1 ALPHAvBETA3 INTEGRIN AS A PREDICTOR OF ENDOMETRIOSIS |
| 01/21/2004 | CN1469879A Substituted 3,4-dihydro-pyrimido[1,2-A] pyrimidines and 3,4-dihydropyrazino [1,2-A] pyrimidines |
| 01/21/2004 | CN1469876A Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 01/21/2004 | CN1469872A A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidine-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b] thiophene hydrochloride |
| 01/21/2004 | CN1469863A Crystal form of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl] piperazine hydrochloride |
| 01/21/2004 | CN1469745A Preventives and remedies for complications of diabetes |
| 01/21/2004 | CN1469739A Method for modulating bladder function |
| 01/21/2004 | CN1469734A Pharmaceutical form of administration for peptides, method for its production and use |
| 01/21/2004 | CN1468622A Recipe and production process of medicine granule for treating prostatitis |
| 01/21/2004 | CN1468619A Compound Chinese medicine prepn for treating benign prostate hyperplasia and its prepn process |
| 01/21/2004 | CN1468595A Honeyed liver and kidney soft extract |
| 01/20/2004 | US6680337 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| 01/20/2004 | US6680330 Rapamycin dialdehydes |
| 01/20/2004 | US6680318 Piperazinomethylbenzamides as delta-opioid receptor agonists |
| 01/20/2004 | US6680317 N-(phenyl)-n*-(2-hydroxy-3-aminosulfonylphenyl)guanidine derivatives; chemokine inhibitors; respiratory, cardiovascular, rheumatic, brain, and nervous system disorders |
| 01/20/2004 | US6680298 Administering polypeptide to increase serum levels; dietetics, hypoglycemic agents; cardiovascular, autoimmune, kidney, metabolic and nervous system disorder treatment |
| 01/20/2004 | US6680170 Polynucleotides encoding STE20-related protein kinases and methods of use |
| 01/15/2004 | WO2004005544A2 Marker genes for determining renal toxicity |
| 01/15/2004 | WO2004005538A1 Method of screening anticancer agent |
| 01/15/2004 | WO2004005314A1 ESTRIENO[3,2-b]/[3,4-c]PYRROLE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS |
| 01/15/2004 | WO2004005285A1 New quinuclidine amide derivatives |
| 01/15/2004 | WO2004005276A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives |
| 01/15/2004 | WO2004005265A1 Quinazoline derivatives |
| 01/15/2004 | WO2004005257A1 Secondary amino anilinic piperidines as mch1 antagonists and uses thereof |
| 01/15/2004 | WO2004005252A1 Azabicyclo derivatives as muscarinic receptor antagonists |
| 01/15/2004 | WO2004004781A1 LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL |
| 01/15/2004 | WO2004004780A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 01/15/2004 | WO2004004779A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 01/15/2004 | WO2004004778A1 Use of cetp inhibitors and optionally hmg coa reductable inhibitors and/or antihypertensive agents |
| 01/15/2004 | WO2004004750A2 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | WO2004004736A1 Novel use of imidazotriazinones |
| 01/15/2004 | WO2004004722A1 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough |
| 01/15/2004 | WO2004004703A1 m-PHENYLENEDIAMINE DERIVATIVE |
| 01/15/2004 | WO2004004702A2 Method to inhibit ischemia and reperfusion injury |
| 01/15/2004 | WO2004004701A1 Remedy for urinary frequency and urinary incontinence |
| 01/15/2004 | WO2004004633A2 Use of tnfalpha antibodies and another drug |
| 01/15/2004 | WO2004004629A2 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| 01/15/2004 | WO2003091247A3 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| 01/15/2004 | WO2003089434A3 IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF |
| 01/15/2004 | WO2003080118A3 Combination of an aldosterone receptor antagonist and a fibric acid derivative |
| 01/15/2004 | WO2003079969A3 Compositions and methods for treating and preventing necrosis |
| 01/15/2004 | WO2003061587A3 USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION |
| 01/15/2004 | WO2003057170A8 Oral insulin therapy |
| 01/15/2004 | WO2003053401A3 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| 01/15/2004 | WO2002096866A3 Thiolalkyl benzoic acid derivatives |
| 01/15/2004 | WO2002072010A3 Taxane prodrugs |
| 01/15/2004 | US20040010148 Antiinflammatory agents, antiallergens, antiproliferative agents, immunosuppressants, antidiabetic agents, cardiovascular disorders |
| 01/15/2004 | US20040010141 Antiinflammatory agents; anticancer agents; rheumatic disorders; cardiovascular disorders |
| 01/15/2004 | US20040010134 Albumin fusion proteins |
| 01/15/2004 | US20040010027 Tumor angiogenesis and metastasis inhibition. |
| 01/15/2004 | US20040010022 2-aminooxazole derivatives |
| 01/15/2004 | US20040010020 Trifluoromethyl-substituted nitrogen compounds; treating type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma |
| 01/15/2004 | US20040010019 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 01/15/2004 | US20040010013 Cannabinoid receptor ligands |
| 01/15/2004 | US20040009998 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 01/15/2004 | US20040009995 Treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade |
| 01/15/2004 | US20040009994 Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions |
| 01/15/2004 | US20040009984 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure |
| 01/15/2004 | US20040009965 Treating hyperproliferative disorders |
| 01/15/2004 | US20040009595 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| 01/15/2004 | US20040009244 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 01/15/2004 | US20040009231 hGH (human growth hormone) formulations for pulmonary administration |
| 01/15/2004 | DE10226326A1 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene 9-alpha-substiuierte estratrienes as selective estrogens effective |
| 01/15/2004 | CA2493860A1 Marker genes for determining renal toxicity |
| 01/15/2004 | CA2492535A1 New quinuclidine amide derivatives |
| 01/15/2004 | CA2492121A1 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| 01/15/2004 | CA2491998A1 Azabicyclo derivatives as muscarinic receptor antagonists |
| 01/15/2004 | CA2491685A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising 1,2-prolpylene glycol |
| 01/15/2004 | CA2491682A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 01/15/2004 | CA2491478A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 01/15/2004 | CA2491464A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives |
| 01/15/2004 | CA2491455A1 Novel use of imidazotriazinones |
| 01/15/2004 | CA2491132A1 Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors |
| 01/15/2004 | CA2490714A1 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |